Literature DB >> 18671459

Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors.

Christian G Huber1, Dieter Naber, Martin Lambert.   

Abstract

BACKGROUND: Up to 50% of first-episode psychosis patients suffer from long-term incomplete remission or treatment resistance. Different definitions for these terms have been used in psychiatric research, making generalized statements about the prevalence and predictors of treatment resistance difficult.
OBJECTIVE: The aim of this study was to give an overview on state-of-the-art definitions of treatment resistance for each of the diagnoses making up the inhomogeneous diagnostic entity 'psychosis' and to analyze the factors leading to treatment resistance.
METHODS: A computerized and manual literature search for relevant articles published within recent years was undertaken.
RESULTS: In addition to symptomatic criteria, patients' functional level and quality of life have to be considered in the definition of treatment resistance. Patient-related, illness-related and treatment-related predictors of treatment resistance and incomplete remission might help to identify subjects at risk and optimize interventions.

Entities:  

Mesh:

Year:  2008        PMID: 18671459     DOI: 10.1517/14656566.9.12.2027

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  14 in total

Review 1.  [Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy].

Authors:  L Deutschenbaur; M Lambert; M Walter; D Naber; C G Huber
Journal:  Nervenarzt       Date:  2014-03       Impact factor: 1.214

2.  Accessing Gene Expression in Treatment-Resistant Schizophrenia.

Authors:  Patricia N Moretti; Vanessa K Ota; Eduardo S Gouvea; Mariana Pedrini; Marcos L Santoro; Fernanda Talarico; Leticia M Spindola; Carolina Muniz Carvalho; Cristiano Noto; Gabriela Xavier; Elisa Brietzke; Ary Gadelha; Rodrigo Bressan; Jair Mari; Sintia Belangero
Journal:  Mol Neurobiol       Date:  2018-01-26       Impact factor: 5.590

3.  Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Enrico Smeraldi; Roberto Cavallaro; Vera Folnegović-Šmalc; Leszek Bidzan; Mehmet Emin Ceylan; Andreas Schreiner
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

4.  Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia.

Authors:  Theresa Wimberley; Christiane Gasse; Sandra Melanie Meier; Esben Agerbo; James H MacCabe; Henriette Thisted Horsdal
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

5.  Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms.

Authors:  Robert McCutcheon; Katherine Beck; Michael A P Bloomfield; Tiago R Marques; Maria Rogdaki; Oliver D Howes
Journal:  J Psychopharmacol       Date:  2015-03-18       Impact factor: 4.153

6.  Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study.

Authors:  Jianhua Chen; Ping Yang; Qian Zhang; Ruirui Chen; Peng Wang; Benxiu Liu; Wensheng Sun; Xuemin Jian; Siying Xiang; Juan Zhou; Ningning Li; Ke Wang; Chengwen Gao; Yanqin Wen; Chuanhong Wu; Jinmai Zhang; Yalin Zhao; Qiangzhen Yang; Meihang Li; Robert Stewart; Yuanchao Sun; Dun Pan; Yujuan Niu; Zhuo Wang; Yifeng Xu; Xingwang Li; Lin He; Zhiqiang Li; Yongyong Shi
Journal:  Transl Psychiatry       Date:  2021-06-03       Impact factor: 6.222

7.  Pro-/antiinflammatory dysregulation in early psychosis: results from a 1-year follow-up study.

Authors:  Borja García-Bueno; Miquel Bioque; Karina S MacDowell; Javier Santabárbara; Mónica Martínez-Cengotitabengoa; Carmen Moreno; Pilar A Sáiz; Esther Berrocoso; Patricia Gassó; M Fe Barcones; Ana González-Pinto; Mara Parellada; Julio Bobes; Juan A Micó; Miguel Bernardo; Juan C Leza
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

8.  Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.

Authors:  J M Stevenson; J L Reilly; M S H Harris; S R Patel; P J Weiden; K M Prasad; J A Badner; V L Nimgaonkar; M S Keshavan; J A Sweeney; J R Bishop
Journal:  Transl Psychiatry       Date:  2016-02-23       Impact factor: 6.222

9.  Rate of and time to symptomatic remission in first-episode psychosis in Northern Malawi: A STROBE-compliant article.

Authors:  Atipatsa Chiwanda Kaminga; Wenjie Dai; Aizhong Liu; Japhet Myaba; Richard Banda; Shi Wu Wen; Xiongfeng Pan
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

10.  Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison.

Authors:  Daeyoung Roh; Jhin-Goo Chang; Sol Yoon; Chan-Hyung Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-12-31       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.